Xerostomia Therapeutics Market Report 2026

Xerostomia Therapeutics Market Overview

• Xerostomia Therapeutics market size has reached to $2.24 billion in 2025 • Expected to grow to $2.79 billion in 2030 at a compound annual growth rate (CAGR) of 4.3% • Growth Driver: The Rise In Chronic Diseases Driving The Growth Of The Market Due To Increasing Sedentary Lifestyles And Long-Term Health Management Needs • Market Trend: Advancements In Xerostomia Therapeutics With Patient Friendly Innovation • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Xerostomia Therapeutics Market?

Xerostomia therapeutics refer to treatments and medications used to manage dry mouth, a condition characterized by reduced saliva production. These therapies aim to alleviate symptoms such as difficulty swallowing and tasting, as well as prevent dental issues. The main types of xerostomia therapeutics are artificial saliva or saliva substitutes, and salivary stimulants. Artificial saliva or saliva substitutes are products designed to mimic the natural properties of saliva, providing lubrication, moisture, and protection to the oral tissues. They are distributed through various channels including hospital pharmacies, retail pharmacies, drug stores, mail order pharmacies, and hypermarkets and supermarkets for adult and pediatric end users.

What Is The Xerostomia Therapeutics Market Growth Forecast?

The xerostomia therapeutics market size is expected to see steady growth in the next few years. It will grow to $2.79 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to growth in otc product availability, increasing cancer therapy side effects, rising self-medication trends, expansion of pharmacy networks, higher focus on quality of life treatments. Major trends in the forecast period include rising incidence of medication-induced dry mouth, growing demand for over-the-counter therapies, increased adoption of artificial saliva products, expansion of retail and mail-order pharmacies, higher focus on oral symptom management.

Global Xerostomia Therapeutics Market Segmentation

1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets 3) By End-User: Adult, Pediatric Subsegments: 1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes 2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges

What Are The Drivers Of The Xerostomia Therapeutics Market?

The rising prevalence of chronic diseases is expected to propel the growth of the xerostomia therapeutics market going forward. Chronic diseases refer to long-lasting medical conditions that persist for months or years, often progressing slowly and requiring ongoing management. The rising prevalence of chronic diseases is primarily due to sedentary lifestyles, as lack of regular physical activity contributes to obesity, cardiovascular problems, diabetes, and other long-term health conditions. Xerostomia therapeutics support chronic diseases by alleviating dry mouth symptoms and improving oral health, nutrition, and medication adherence, which are critical factors in managing long-term conditions. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the rising prevalence of chronic diseases is driving the growth of the xerostomia therapeutics industry. The growing geriatric population is expected to propel the growth of the xerostomia therapeutics market going forward. Geriatric population refers to the rising number of individuals aged 65 years and older within the global demographic profile. The increase in the geriatric population is driven by declining fertility rates and rising life expectancy worldwide. The xerostomia therapeutics market supports older adults by providing saliva-stimulating agents and oral moisturizers that reduce dry-mouth symptoms, aiding in chewing, swallowing, and maintaining nutrition. For instance, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, in 2022, there were 12.7 million people aged 65 or older in the UK, representing 19% of the total population. This number is projected to rise to 22.1 million by 2072, accounting for 27% of the population. Therefore, the growing geriatric population is driving the growth of the xerostomia therapeutics industry.

Key Players In The Global Xerostomia Therapeutics Market

Major companies operating in the xerostomia therapeutics market are GlaxoSmithKline plc, Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Synedgen Inc., Mission Pharmacal Company, Dentaid Ltd., Sunstar Suisse S.A., Forward Science Holding Inc., OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc., Saliwell Limited, Bayer AG, 3M Company, Church & Dwight Co. Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Teva Pharmaceutical Industries Ltd.

Global Xerostomia Therapeutics Market Trends and Insights

Major companies operating in the xerostomia therapeutics market are focusing on patient-friendly, non-invasive treatments, such as oral sprays that provide precise topical lubrication and protective barrier coverage across the mouth to relieve dry-mouth symptoms and support oral health. Oral sprays for xerostomia refer to formulations delivered as fine mist directly onto the oral mucosa (tongue, palate, inner cheeks) which form either a hydrating film or lipid-based coating to reduce moisture evaporation, enhance lubrication during chewing/swallowing/speaking, and deliver longer duration relief in patients prone to dry mouth. For instance, in July 2023, K Pharmaceuticals, a US-based (India-origin reference notwithstanding) pharmaceutical company, launched Aquoral, a clinically-proven oral spray for managing xerostomia that uses patented Oxidized Glycerol Triesters (OGT) lipid technology to form a long-lasting protective barrier over the oral cavity, offering up to six hours of relief, enabling two quick sprays, and reducing the need for frequent reapplication compared to aqueous-based treatments.

Regional Insights

North America was the largest region in the xerostomia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Xerostomia Therapeutics Market?

The xerostomia therapeutics market consists of revenues earned by entities by providing services such as medical consultations, pharmacological assistance, dental care, patient education, support services, and research and development, all geared towards treating and managing dry mouth. The market value includes the value of related goods sold by the service provider or included within the service offering. The xerostomia therapeutics market also includes sales of oral moisturizers, dental products such as fluoride treatments and saliva-stimulating mouthwashes, and oral lubricants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Xerostomia Therapeutics Market Report 2026?

The xerostomia therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the xerostomia therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.